Cambridge Investment Research Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$2.21M Buy
45,467
+6,278
+16% +$305K 0.01% 1361
2025
Q1
$1.33M Buy
39,189
+4,914
+14% +$167K ﹤0.01% 1640
2024
Q4
$1.35M Buy
34,275
+9,973
+41% +$393K ﹤0.01% 1638
2024
Q3
$1.14M Sell
24,302
-4,238
-15% -$199K ﹤0.01% 1768
2024
Q2
$1.54M Sell
28,540
-27,797
-49% -$1.5M 0.01% 1468
2024
Q1
$3.84M Buy
56,337
+8,408
+18% +$573K 0.01% 897
2023
Q4
$3M Buy
47,929
+24,839
+108% +$1.55M 0.01% 969
2023
Q3
$1.05M Sell
23,090
-2,040
-8% -$92.6K ﹤0.01% 1543
2023
Q2
$1.41M Sell
25,130
-712
-3% -$40K 0.01% 1380
2023
Q1
$1.17M Sell
25,842
-861
-3% -$38.9K 0.01% 1474
2022
Q4
$1.09M Buy
26,703
+710
+3% +$28.8K 0.01% 1472
2022
Q3
$1.7M Sell
25,993
-1,545
-6% -$101K 0.01% 1125
2022
Q2
$1.67M Buy
27,538
+5,708
+26% +$347K 0.01% 1133
2022
Q1
$1.37M Buy
21,830
+4,801
+28% +$301K 0.01% 1371
2021
Q4
$1.29M Sell
17,029
-5,077
-23% -$385K 0.01% 1416
2021
Q3
$2.47M Sell
22,106
-5,382
-20% -$602K 0.01% 980
2021
Q2
$4.45M Buy
27,488
+7,726
+39% +$1.25M 0.02% 680
2021
Q1
$2.41M Buy
19,762
+2,015
+11% +$246K 0.01% 922
2020
Q4
$2.72M Buy
17,747
+6,690
+61% +$1.02M 0.02% 768
2020
Q3
$925K Buy
11,057
+4,656
+73% +$390K 0.01% 1234
2020
Q2
$470K Buy
6,401
+498
+8% +$36.6K ﹤0.01% 1591
2020
Q1
$250K Sell
5,903
-995
-14% -$42.1K ﹤0.01% 1784
2019
Q4
$420K Sell
6,898
-5,984
-46% -$364K ﹤0.01% 1689
2019
Q3
$528K Sell
12,882
-18,181
-59% -$745K ﹤0.01% 1463
2019
Q2
$1.46M Buy
+31,063
New +$1.46M 0.01% 839
2018
Q4
Sell
-7,670
Closed -$340K 2178
2018
Q3
$340K Buy
+7,670
New +$340K ﹤0.01% 1716